HC Wainwright Brokers Lower Earnings Estimates for Merus

Merus (NASDAQ:MRUS) – HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Merus in a research note issued to investors on Thursday, May 8th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of ($1.28) for the quarter, down from their previous estimate of ($1.24). HC Wainwright currently has a “Buy” rating and a $85.00 target price on the stock. The consensus estimate for Merus’ current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Merus’ Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.15) EPS, FY2026 earnings at ($4.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($1.79) EPS.

Several other brokerages have also commented on MRUS. William Blair reaffirmed an “outperform” rating on shares of Merus in a research note on Monday, April 28th. Bank of America decreased their price target on Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Wells Fargo & Company decreased their price target on Merus from $91.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $83.00 price target on shares of Merus in a research note on Wednesday, April 9th. Finally, Piper Sandler initiated coverage on Merus in a research note on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target on the stock. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $85.15.

Merus Price Performance

Shares of MRUS stock opened at $40.92 on Monday. The stock’s fifty day simple moving average is $43.43 and its 200 day simple moving average is $43.96. The firm has a market cap of $2.83 billion, a price-to-earnings ratio of -10.36 and a beta of 0.94. Merus has a one year low of $33.19 and a one year high of $61.61.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The company had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%.

Hedge Funds Weigh In On Merus

Several large investors have recently made changes to their positions in MRUS. GAMMA Investing LLC lifted its stake in shares of Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 603 shares during the period. State of Wyoming acquired a new position in shares of Merus during the fourth quarter valued at $48,000. Wells Fargo & Company MN lifted its stake in shares of Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 300 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Merus during the fourth quarter valued at $60,000. Finally, Avior Wealth Management LLC acquired a new position in shares of Merus during the fourth quarter valued at $76,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.